Abstract 787 Figure 1 Kaplan meier curves for patients who completed NACT followed by radical local treatment (CTR/RT + brachytherapy boost)

Abstract 787 Table 1 Univariate analysis of correlation of prognostic factors with LC, RC, DMC, RFS and OS

Variables		Local Control	Regional Control	Distant Metastasis Control	Disease Free Survival	Overall Survival
Age (years)	<52	0.260	0.482	0.937	0.623	0.792
	≥ 52					
Comorbidities	No	0.590	0.019	0.942	0.349	0.139
	Yes					
Stage	IIIC1	0.109	0.826	0.196	0.944	0.671
	IIIC2					
	IVA					
Reason for giving NACT	Bladder invasion	0.012	0.750	0.076	0.986	0.701
	Others					
Nodal Site	Pelvic nodes	0.503	0.037	0.088	0.041	0.110
	Others					
Maximum Pelvic node size (cm)	< 2.5	0.911	0.234	0.137	0.232	0.007
	≥ 2.5					
Maximum Para-aortic node size (cm)	< 1.8	0.996	0.669	0.121	0.459	0.507
	≥ 1.8					
NACT dose reduction	No	0.001	0.061	0.386	0.003	0.022
	Yes					
Post NACT	Completed radical treatment	0.000	0.000	0.436	0.000	0.000
	Not completed radical treatment					
Nodal Boost	No	0.143	0.986	0.259	0.939	0.642
	Yes					

analysis, none of the variables reached levels of significance. At median follow-up of 26 months (IQR: 11-45), 34 patients had died of disease, 51 were alive, of which 34 were disease-free. The 2 year LC, RC, DMC, DFS and OS for the entire cohort was 75%, 68%, 72%, 48% and 60% respectively whereas for the patents who completed NACT and radical local treatment was 92%, 82%, 76%, 62% and 75% respectively (figure 1).

Conclusion* NACT followed by radiation therapy in non metastatic advanced cervical cancer is a feasible option with good survival outcomes and acceptable toxicity.

820

LATERALLY EXTENDED PELVIC RESECTION WITH COMPLETE RESECTION OF URETER AND NEPHRECTOMY

M Zikan*, O Dubova, P Koliba, V Student, T Brtnicky, P Kabele. *Charles University – First Faculty of Medicine and Bulovka University Hospital, Dept. of Gynecology and Obstetrics, Praha 8, Czech Republic*

10.1136/ijgc-2021-ESGO.71

Introduction/Background* Laterally extended endopelvic resection became a standard surgical approach for pelvic tumors, recurrences specifically, localized laterally in the pelvis. This

technique represents other possibility, besides pelvic exenteration for tumors located laterally.

Methodology Video presentation of laterally extended endopelvic resection in patient with cervical cancer recurrence after radiotherapy localized laterally in the left obturator fossa and residual parametria and paracolpium with complete obstruction of ureter and afunctional left kidney.

Result(s)* Recurrent tumor was removed in toto with resection of internal iliac vessel, residual parametria and paracolpium and complet resection of infiltrated ureter.

Conclusion* Technique of laterally extended endopelvic resection allows – due to precise knowledge of pelvic structures and their topography – for safe removal of even laterally located tumor deep in the pelvis/pevic floor.

848 INDOCYANINE GREEN TO ASSESS VASCULARITY OF BRICKER ILEAL CONDUIT ANASTOMOSIS DURING PELVIC EXENTERATION FOR RECURRENT CERVICAL CANCER

¹N Bizzarri*, ²N Foschi, ¹M Loverro, ¹L Tortorella, ³F Santullo, ¹A Rosati, ¹S Gueli Alletti, ¹B Costantini, ¹V Gallotta, ¹MG Ferrandina, ¹A Fagotti, ¹F Fanfani, ¹G Scambia, ¹AG Vizzielli. ¹Fondazione Policlinico Universitario A. Gemelli, IRCCS, UOC Ginecologia Oncologica, Dipartimento per la salute della Donna e del Bambino e della Salute Pubblica, Rome, Italy; ²Fondazione Policlinico Universitario A. Gemelli, IRCCS, UOC Clinica Urologica, Rome, Italy; ³Fondazione Policlinico Universitario A. Gemelli, IRCCS, UOC Chirurgia Peritoneo e Retroperitoneo, Rome, Italy; ⁴Academic Hospital of Udine, Obstetrics and Gynecology Department, Udine, Italy

10.1136/ijgc-2021-ESGO.72

Introduction/Background* Pelvic exenteration performed for recurrent cervical cancer has been associated to urological short- and long-term morbidity, due to altered vascularization of tissues for previous radiotherapy. The aim of the present video is to demonstrate the use of intravenous indocyanine green (ICG) to assess vascularity of Bricker ileal conduit after pelvic exenteration for recurrent cervical cancer and to evaluate the feasibility and safety of this technique.

Methodology The patient was a 64-year-old woman who underwent exclusive chemoradiation for FIGO stage IIB cervical SCC. Seven months after the end of the radiotherapy she was diagnosed with an isolated central pelvic recurrence involving bladder wall. The patient underwent open total pelvic exenteration with Bricker ileal conduit urinary diversion and end sigmoid colostomy. After performing the anastomoses, the perfusion of tissues was analyzed with intravenous injection of 3 ml of ICG and a (1.25 mg/ml) and a near infra-red SPY Portable Handheld Imager (SPY-PHI) (Stryker, Kalamazoo, Michigan, US). After ICG injection, a four-tier (+++ versus ++- versus +- versus -) classification was used to assess the vascularity of each anastomosis: ileum-ileum, right and left ureter with small bowel. The classification of ICG perfusion of anastomoses was independently performed by the urologist and the gynecologic oncologist.

Result(s)* Intravenous injection did not cause any adverse event. After ICG injection, the left ureter-ileal conduit demonstrated sub-optimal vascularization (—), the right ureter-ileal conduit and the ileum-ileum showed optimal vascularization (+++). ICG perfusion is demonstrated with three different modalities: Overlay Fluorescence Mode, Color Segmented Fluorescence Mode, Contrast Fluorescence Mode. Patient developed benign left ureteric stricture which was diagnosed with a CT-scan 45 days after the radical surgery and was treated with antegrade ureteric stenting.

Conclusion* The use of ICG to intra-operatively assess the anastomoses perfusion at time of pelvic exenteration for gynecologic malignancy is a feasible and safe technique. The different vascularization of anastomotic stumps may be related to anatomical sites and to previous radiation treatment and it may be useful to predict post-operative complications. This approach could be of support in selecting patients at higher risk of complications, who may need personalized follow up.

854 SURGICAL LYMPH NODE STAGING IN LOCALLY ADVANCED CERVICAL CARCINOMA

¹M Imterat*, ¹M Moubarak, ²KU Waltering, ³K Berkovic, ³I Stöver, ³A Koziorowski, ¹A B Ataseven, ¹P Harter, ¹A Du Bois, ¹N Concin. ¹Ev. Kliniken Essen-Mitte, Department of Gynecology and Gynecologic Oncology, Essen, Germany; ²Ev. Kliniken Essen-Mitte, Department of Radiology, Essen, Germany; ³Ev. Kliniken Essen-Mitte, Department of Radiotherapy, Essen, Germany; ⁴University Hospital, LMU Munich, Department of Obstetrics and Gynecology, Munich, Germany

10.1136/ijgc-2021-ESGO.73

Introduction/Background* Radiation field planning in patients with locally advanced cervical cancer (LACC) undergoing primary definitive chemoradiotherapy is influenced by lymph

Abstract 854 Table 1 Patients demographic and tumor characteristics according to pathological (pelvic and paraaortic) lymph-node status

Characteristics	Negative Lymph-node N= 14 (24.1%)	Positive lymph-node N= 44 (75.9%)	Entire cohort N= 58	p-value
Patient age, years, median (Range)	59.5 (32-72)	51 (26-80)	53 (26-80)	0.228
ECOG* score:	13 (92.9)	41 (93.2)	54 (93.1)	1.000
0	1 (7.1)	3 (6.8)	4 (6.9)	
>0				
Preoperative imaging technique:				
CT	14 (100)	42 (95.5)	56 (96.6)	0.417 (CT)
MRI	11 (78.6)	40 (90.9)	51 (87.9)	0.217 (MRI)
Histological type:	13 (92.9)	39 (88.6)	52 (89.7)	0.719
squamous cell	1 (7.1)	3 (6.8)	4 (6.9)	
sdenocarcinoma small cell	0	2 (4.5)	2(3.4)	
Grading:	6 (42.9)	15 (34.1)	21 (36.2)	0.799
G2	7 (50)	24 (54.5)	31 (53.4)	
G3	1 (7.1)	5 (11.4)	6 (10.3)	
GX				
cT classification:	0	12 (27.3)	12 (20.7)	0.004
1b1	0	2 (4.5)	2 (3.4)	
1b2	0	2 (4.5)	2 (3.4)	
2a1	1 (7.1)	7 (15.9)	8 (13.8)	
2a2	7 (50)	11 (25)	18 (31)	
2b	0	3 (6.8)	3 (5.2)	
3a	1 (7.1)	6 (13.6)	7 (12.1)	
3b	5 (35.7)	1 (2.3)	6 (10.3)	
4a				
Lymph-node site:		26 (59.1)	26 (44.8)	
pelvic paraaortic pelvic		6 (13.6)	6 (10.3)	
+paraaortic		12 (27.3)	12 (20.7)	

Data are presented as n (%); Significance was measured using Chi squared * Eastern Cooperative Oncology Group